(Reuters) - Britain's Oxford BioMedica OXB.L has agreed with AstraZeneca to manufacture the drugmaker's experimental COVID-19 vaccine, the cell therapy company said on Thursday.
Oxford BioMedica will provide the drugmaker withmultiple batches of the vaccine, called AZD1222, under a one-year clinical and commercial supply agreement, the company said, adding that the majority of it is expected be produced throughout 2020.
Oxford BioMedica shares were up 7.3% at 769 pence after the announcement.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.